Pharsight Expands Strategic Consulting Ser...( Pharsight Strengthens US Team with...)

Pharsight Strengthens US Team with Addition of Jonathan Monteleone and

Herbert Struemper

MOUNTAIN VIEW, Calif., Sept. 10 /PRNewswire-FirstCall/ -- Pharsight Corporation (OTC Bulletin Board: PHST), a leading provider of software and strategic services for optimizing clinical drug development, today announced that it has hired Jonathan Monteleone, M.S., and Herbert Struemper, Ph.D., as senior associate scientists in the Company's Strategic Consulting Services group. Both Mr. Monteleone and Dr. Struemper will be based in the United States out of Pharsight's Cary, North Carolina office.

"The addition of two new scientists is another key step as we continue to grow our world class consulting team at Pharsight," said Shawn O'Connor, president, chief executive officer and chairman of Pharsight. "Dr. Struemper and Mr. Monteleone both have a unique combination of deep technical expertise and knowledge of drug development decision-making processes that will be of significant value to our consulting team. We look forward to their contributions that we believe will further enhance the services that we can provide to our clients."

Dr. Struemper comes to Pharsight from Entelos Incorporated, where he led in silico research and development projects in rheumatoid arthritis, obesity and diabetes. He has broad experience in biomarker identification and evaluation, drug-disease modeling, and clinical trial design and simulation. Dr. Struemper holds a Ph.D. in Electrical Engineering from the University of Maryland in College Park. He also completed a postdoctoral research fellowship at the California Institute of Technology in Pasadena, California, where he designed motion control algorithms for nonlinear robotic systems. Dr. Struemper holds four life sciences patents, including two patents on methods for computer modeling of human physiological processes.

Mr. Monteleone joins Pharsight from Dov Pharmaceuticals, where he focu
'/>"/>